Rodrigues, TiagoBernardes, Gonçalo J. L.2021-12-022021-12-022018Angew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-20341433-7851http://hdl.handle.net/10451/50253© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.engAnti-tumor agentsAntibody-drug conjugatesBioconjugationDrug deliveryLinkersjournal article10.1002/anie.2017121851521-3773